- Record: found
- Abstract: found
- Article: not found
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode
1 ,
Nicole Forestier ,
Geoffrey Dusheiko ,
Peter Ferenci ,
Stanislas Pol ,
Tobias Goeser ,
Jean-Pierre Bronowicki ,
Marc Bourlière ,
Shahin Gharakhanian ,
Leif Bengtsson ,
Lindsay McNair ,
Shelley George ,
Tara Kieffer ,
Ann Kwong ,
Robert S Kauffman ,
John Alam ,
Jean-Michel Pawlotsky ,
Stefan Zeuzem
Apr 30 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%. Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment.